Clinical Trials Logo

Clinical Trial Summary

This clinical imaging substudy will use the small molecule translocator protein (TSPO) ligand, Fludeoxyglucose(18F)-labeled DPA-714, to compare neuroinflammation in individuals with high or low grade asymptomatic carotid artery stenosis (aCAD) who are participating in the separate Neuroinflammation in Asymptomatic Carotid Artery Disease study lead by Dr. Ron Lazar (IRB-300007806). The positron emission tomography (PET) tracer [18F]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05238961
Study type Interventional
Source University of Alabama at Birmingham
Contact Evan Hudson
Phone 205-934-6499
Email evanhudson@uabmc.edu
Status Recruiting
Phase Phase 1
Start date April 1, 2025
Completion date December 31, 2026